Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First Patient Dosed in Decoy20 trial for Advanced Solid Tumors

May 29, 2024

Ph 1 Trial of PSMA-Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Prostate Cancer

May 21, 2024

First Patient Dosed in Investigator-Initiated Trial (IIT) of Danvatirsen in Ph 1 for AML/MDS Cancers

May 21, 2024

First Patient Dosed in EVEREST-2 Ph 1 Trial of Novel Mesothelin Logic-Gated CAR T

May 21, 2024

First Patient Dosed in Ph 1 Clinical Trial of CT-0525

May 21, 2024

RAPHAEL Registrational Ph 3 Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated R/R AML in China Initiated

May 21, 2024

Enrollment Completed in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 21, 2024

First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML

May 21, 2024

Further development of trastuzumab imbotolimod (BDC-1001) to be ceased

May 21, 2024

Ph 3 KeyVibe-010 Trial of Vibostolimab + Pembrolizumab coformulation as Adjuvant Treatment for Resected High-Risk Melanoma unlikely to achieve a statistically significant RFS improvement

May 15, 2024

5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data

May 15, 2024

Randomized Portion (Part 2) of REFRαME-O1 Trial of luvelta for patients with platinum-resistant ovarian cancer (PROC) initiated

May 7, 2024

First Patient Dosed in Ph 2 Trial of INB-400 in Newly Diagnosed GBM

May 7, 2024

First Patient Dosed in Ph 1/1b MYTHIC Trial of PKMYT1 and WEE1 Inhibition

May 7, 2024

Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated

May 7, 2024

First Patient Dosed in Investigator-Initiated Ph 2 Trial of GB1211 + Pembrolizumab

May 7, 2024

First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS

May 7, 2024

Ph 1 Trial for BG1805, a CAR-T Targeting CLL-1, initiated

May 7, 2024

First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 7, 2024

Positive Recommendation of IDMC Following Completion of Enrollment in REGAL Ph 3 Study Announced

May 1, 2024

Ph 2 trial of VB10.16 with or without Tecentriq initiated for the treatment of HPV16+ve, PD-L1+ve, recurrent or metastatic cervical cancer

May 1, 2024

First Cohort Completed and Second Cohort of Ph 1/2 Study of INKmune™ NK Cell Therapy in Patients with Metastatic CRPC Initiated

May 1, 2024

First Patient Dosed in Ph 1 Study of CTX-8371 in Patients with Solid Tumors

May 1, 2024

Enrollment Completed in STAR-LLD Ph 1b Trial in Multiple Myeloma

May 1, 2024

Move-Forward Ph 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous NSCLC selected

April 23, 2024
Page1 … Page9 Page10 Page11 Page12 Page13 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.